GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT02065063
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 79
- Registration Number
- NCT02064387
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects
Phase 1
Terminated
- Conditions
- Bronchiectasis
- Interventions
- Drug: GSK2793660 solutionDrug: GSK2793660 capsuleDrug: Placebo capsuleDrug: Placebo solution
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT02058407
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant
Phase 3
Completed
- Conditions
- Herpes Zoster
- Interventions
- Drug: PlaceboBiological: Herpes Zoster vaccine GSK1437173A
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 265
- Registration Number
- NCT02058589
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2017-08-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 222
- Registration Number
- NCT02058628
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia
Phase 3
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Disintegrating placebo tamsulosin tablet
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 607
- Registration Number
- NCT02058368
- Locations
- 🇨🇳
GSK Investigational Site, Tau-Yuan, Taiwan
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State
Phase 1
Completed
- Conditions
- Urologic Diseases
- Interventions
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 77
- Registration Number
- NCT02058576
- Locations
- 🇬🇧
GSK Investigational Site, Belfast, United Kingdom
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
Phase 1
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Other: Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT02058602
- Locations
- 🇧🇪
GSK Investigational Site, Edegem, Belgium
Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
Phase 3
Completed
- Conditions
- RubellaMeaslesMumps
- Interventions
- Biological: Priorix®Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 996
- Registration Number
- NCT02058563
- Locations
- 🇸🇰
GSK Investigational Site, Zlate Moravce, Slovakia
Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT02058641
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath